Targeting cancer with power and precision


Sesen Bio, Inc. (NASDAQ: SESN), previously Eleven Biotherapeutics, Inc., is a late-stage company developing next-generation antibody-drug conjugate (ADC) therapies for patients with cancer. Their approach aims to overcome limitations of traditional ADCs by incorporating a tumor-targeting antibody fragment and a protein cytotoxic payload into a single protein molecule designed to selectively, effectively and broadly kill cancer cells while sparing healthy cells. These single protein molecules are known as fusion proteins. Their lead program, Vicinium™, is a novel fusion protein currently in Phase 3 development for the treatment of patients with non-muscle invasive bladder cancer who have been previously treated with bacillus Calmette-Guérin (BCG).


Year Invested: 2010
Location: Cambridge, Mass.
Visit: www.sesenbio.com

Recent News

March 4, 2019
Sesen Bio Reports Fourth Quarter and Full-Year 2018 Financial Results and Additional Preliminary Data from Phase 3 VISTA Trial

February 25, 2019
Sesen Bio to Host Conference Call to Review Fourth Quarter and Full-Year 2018 Financial Results and Additional Preliminary Data from Phase 3 VISTA Trial

January 3, 2019
Sesen Bio Announces Positive Preliminary 12-Month Data from Registration Phase 3 VISTA Trial of Vicinium for Non-Muscle Invasive Bladder Cancer

Read More News

Associated Team Members

Cary Pfeffer, M.D.
Partner

Abbie Celniker, Ph.D.
Partner